NCT03208257

Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Samuel Brown · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Septic shock is a common syndrome caused by the body's response to an infection. Septic shock is responsible for 10% of all ICU admissions and 30% of ICU deaths. Use of "beta blocker" medications may improve outcomes after septic shock. This pilot study evaluates protocols to infuse the beta blocker esmolol in patients with septic shock.

Detailed description

This is a prospective, single arm, feasibility study of esmolol infusion in septic shock. The objective is to evaluate the feasibility, adequacy, and efficiency of study protocols for a subsequent ECASSS study. This study (ECASSS-R2) extends observations made in an initial pilot, ECASSS-R.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	Esmolol	Esmolol hydrochloride infusion

Timeline

• Start date: 2017-08-07
• Primary completion: 2020-12-01
• Completion: 2021-06-01
• First posted: 2017-07-05
• Last updated: 2019-02-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study